S'abonner

Sputum mast cell/basophil gene expression relates to inflammatory and clinical features of severe asthma - 04/08/21

Doi : 10.1016/j.jaci.2021.01.033 
Natasha A. Winter, BBiomedSc(Hons) a, b, c, , Ling Qin, MD d, , Peter G. Gibson, DMed, FRACP, FAPSR, FAHMS a, b, c, e, Vanessa M. McDonald, BNurs, PhD a, b, f, Katherine J. Baines, PhD b, Jack Faulkner, BMath(Hons) g, Tiffany-Jane Evans, MMedStat g, Michael Fricker, PhD a, b, c,
a National Health and Medical Research Council Centre for Research Excellence in Severe Asthma, Newcastle, Australia 
b The Priority Research Centre for Health Lungs, The University of Newcastle, Newcastle, Australia 
c School of Medicine and Public Health, The University of Newcastle, Newcastle, Australia 
d Department of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, China 
e Department of Respiratory and Sleep Medicine, John Hunter Hospital, Hunter Medical Research Institute, Newcastle, Australia 
f School of Nursing and Midwifery, The University of Newcastle, Newcastle, Australia 
g Clinical Research Design, IT and Statistical Support Unit, Hunter Medical Research Institute, Newcastle, Australia 

Corresponding author: Michael Fricker, BSc, PhD, Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, Lot 1 Kookaburra Circuit, New Lambton Heights, NSW 2305, Australia.Priority Research Centre for Healthy LungsHunter Medical Research InstituteLot 1 Kookaburra CircuitNew Lambton HeightsNSW2305Australia

Abstract

Background

Mast cells (MCs) and basophils are important in asthma pathophysiology, however direct measurement is difficult, and clinical and inflammatory associations in severe asthma are poorly understood. Transcriptomic hallmarks of MCs/basophils may allow their measurement in sputum using gene expression.

Objectives

This study sought to develop and validate a sputum MC/basophil gene signature and investigate its relationship to inflammatory and clinical characteristics of severe asthma.

Methods

A total of 134 candidate MC/basophil genes (identified by the Immunological Genome Project Consortium) were screened in sputum microarray for differential expression among control subjects (n = 18), patients with eosinophilic (n = 29), and patients with noneosinophilic asthma (n = 30). Candidate genes were validated by confirming correlation of gene expression with flow cytometry-quantified sputum MCs and basophils in a separate asthma cohort (n = 20). The validated gene signature was measured in a severe asthma cohort (n = 81), and inflammatory and clinical associations were tested.

Results

Through microarray screening and subsequent validation, we found quantitative PCR gene expression of 8 targets correlated with sputum MCs/basophils: TPSAB1/TPSB2, CPA3, ENO2, GATA2, KIT, GPR56, HDC, SOCS2. In severe asthma, MC/basophil genes were associated with eosinophilic airway inflammation (GATA2, TPSB2, CPA3, GPR56, HDC, SOCS2), blood eosinophils (TPSB2, CPA3, GATA2, SOCS2, FCER1A, HDC), fractional exhaled NO (GATA2, SOCS2), decreased lung function (KIT, ENO2), and moderate exacerbation history (GATA2, SOCS2).

Conclusions

Quantitative PCR–based measures reflect varying sputum MC/basophil abundance, demonstrating associations of MCs/basophils with eosinophilic inflammation, spirometry and exacerbation history in severe asthma.

Le texte complet de cet article est disponible en PDF.

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Key words : Mast cells, basophils, asthma, gene expression, inflammation

Abbreviations used : ACQ, AHR, ASM, AUROC, BR, EA, Feno, FVC, LASSO, MC, NA, NEA, NNA, PBEs, ppb


Plan


 This work was supported by grants from the National Health and Medical Research Council (G1400017); University of Newcastle (G1101050); Hunter Medical Research Institute (G1101169); and John Hunter Hospital Charitable Trust (G1200211). M.F. received funding from a Thoracic Society of Australia and New Zealand/AstraZeneca Respiratory Research Fellowship. K.J.B. was supported by a Lung Foundation Australia chronic obstructive pulmonary disease research fellowship. Sponsors had no role in study design, analysis or interpretation of results, or preparation of manuscript.
 Disclosure of potential conflict of interest: P.G. Gibson has received personal fees from AstraZeneca, GlaxoSmithKline and Novartis; and grants from AstraZeneca and GlaxoSmithKline outside the submitted work. V.M. McDonald has received research funding from the National Health and Medical Research Council, the Ramaciotti Foundation, the University of Newcastle, The Hunter Medical Research Institute, and the John Hunter Hospital Research Grants Scheme in relation to the presented work; personal fees from AstraZeneca, GlaxoSmithKline, and Menarini; and grants from AstraZeneca and GlaxoSmithKline outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.


© 2021  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 148 - N° 2

P. 428-438 - août 2021 Retour au numéro
Article précédent Article précédent
  • Managing respiratory emergencies at school: A county-wide stock inhaler program
  • Ashley A. Lowe, Joe K. Gerald, Conrad J. Clemens, Debra A. Stern, Lynn B. Gerald
| Article suivant Article suivant
  • Studies of the role of basophils in aspirin-exacerbated respiratory disease pathogenesis
  • Whitney W. Stevens, Anna G. Staudacher, Kathryn E. Hulse, Julie A. Poposki, Atsushi Kato, Roderick G. Carter, Lydia A. Suh, James E. Norton, Julia H. Huang, Anju T. Peters, Leslie C. Grammer, David B. Conley, Stephanie Shintani-Smith, Bruce K. Tan, Kevin C. Welch, Robert C. Kern, Robert P. Schleimer

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.